{"transactions":[{"id":702781,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-27T23:30:05.000Z","date":"2026-07-24","kind":"sale","planned":false,"acquired":false,"shares":12500,"price":11.714,"value":146425.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":702770,"source":{"system":"sec-edgar","filing":"0001831410-26-000008","document":"form4-07272026_070701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000008/form4-07272026_070701.xml","form_type":"4"}},{"id":702780,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-27T23:30:05.000Z","date":"2026-07-23","kind":"sale","planned":false,"acquired":false,"shares":12500,"price":11.579,"value":144737.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":715270,"source":{"system":"sec-edgar","filing":"0001831410-26-000008","document":"form4-07272026_070701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000008/form4-07272026_070701.xml","form_type":"4"}},{"id":728554,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T21:30:23.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001831410-26-000006","document":"form4-06232026_090619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000006/form4-06232026_090619.xml","form_type":"4"}},{"id":934006,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T02:00:05.000Z","date":"2026-01-20","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":26.88,"value":268800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"2. The weighted average sale price for the transaction reported was $26.88, and the range of prices were between $26.85 and $26.96. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":727770,"source":{"system":"sec-edgar","filing":"0001831410-26-000004","document":"form4-01212026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000004/form4-01212026_090101.xml","form_type":"4"}},{"id":936722,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-17T02:00:06.000Z","date":"2026-01-14","kind":"sale","planned":false,"acquired":false,"shares":3489,"price":29.12,"value":101599.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $29.12, and the range of prices were between $29.00 and $29.23. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":737770,"source":{"system":"sec-edgar","filing":"0001831410-26-000002","document":"form4-01162026_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141026000002/form4-01162026_090101.xml","form_type":"4"}},{"id":957857,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T02:55:05.000Z","date":"2025-12-22","kind":"sale","planned":false,"acquired":false,"shares":2881,"price":28.53,"value":82194.93,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $28.53, and the range of prices was between $28.50 and $28.53. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":741259,"source":{"system":"sec-edgar","filing":"0001831410-25-000007","document":"form4-12292025_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000007/form4-12292025_091201.xml","form_type":"4"}},{"id":1036060,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T01:30:05.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":3086,"price":8.32,"value":25675.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $8.32, and the range of prices was between $8.29 and $8.33. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager."}],"balance_after":117028,"source":{"system":"sec-edgar","filing":"0001831410-25-000004","document":"form4-09182025_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000004/form4-09182025_090901.xml","form_type":"4"}},{"id":1036059,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T01:30:05.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":1914,"price":8.08,"value":15465.12,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $8.08, and the range of prices was between $8.04 and $8.08. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager."}],"balance_after":120114,"source":{"system":"sec-edgar","filing":"0001831410-25-000004","document":"form4-09182025_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000004/form4-09182025_090901.xml","form_type":"4"}},{"id":1036058,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T01:30:05.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":8.33,"value":83300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $8.33, and the range of prices was between $8.28 and $8.37. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":744140,"source":{"system":"sec-edgar","filing":"0001831410-25-000004","document":"form4-09182025_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000004/form4-09182025_090901.xml","form_type":"4"}},{"id":1036057,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-19T01:30:05.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":8.04,"value":80400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $8.04, and the range of prices was between $8.02 and $8.09. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":754140,"source":{"system":"sec-edgar","filing":"0001831410-25-000004","document":"form4-09182025_090901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000183141025000004/form4-09182025_090901.xml","form_type":"4"}},{"id":1110976,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:18.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017234","document":"form4-06132025_050615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925017234/form4-06132025_050615.xml","form_type":"4"}},{"id":1335024,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-12T00:56:44.000Z","date":"2024-12-11","kind":"sale","planned":false,"acquired":false,"shares":179,"price":9.39,"value":1680.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":764140,"source":{"system":"sec-edgar","filing":"0001415889-24-029028","document":"form4-12122024_121240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924029028/form4-12122024_121240.xml","form_type":"4"}},{"id":1335023,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-12T00:56:44.000Z","date":"2024-12-11","kind":"sale","planned":false,"acquired":false,"shares":7958,"price":8.66,"value":68916.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":764319,"source":{"system":"sec-edgar","filing":"0001415889-24-029028","document":"form4-12122024_121240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924029028/form4-12122024_121240.xml","form_type":"4"}},{"id":1335022,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-12T00:56:44.000Z","date":"2024-12-10","kind":"sale","planned":false,"acquired":false,"shares":8256,"price":9.37,"value":77358.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.89 and $9.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":772277,"source":{"system":"sec-edgar","filing":"0001415889-24-029028","document":"form4-12122024_121240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924029028/form4-12122024_121240.xml","form_type":"4"}},{"id":1335021,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-12T00:56:44.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":29250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 11, 2022, the Reporting Person was granted certain performance restricted stock units (\"PRSUs\") for 45,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria."}],"balance_after":780533,"source":{"system":"sec-edgar","filing":"0001415889-24-029028","document":"form4-12122024_121240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924029028/form4-12122024_121240.xml","form_type":"4"}},{"id":1445066,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-31T21:15:05.000Z","date":"2024-07-30","kind":"sale","planned":true,"acquired":false,"shares":934,"price":15.55,"value":14523.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $15.55, and the range of prices was between $15.55 and $15.58. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":751283,"source":{"system":"sec-edgar","filing":"0001415889-24-020461","document":"form4-07312024_050701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924020461/form4-07312024_050701.xml","form_type":"4"}},{"id":1445065,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-31T21:15:05.000Z","date":"2024-07-29","kind":"sale","planned":true,"acquired":false,"shares":4066,"price":15.58,"value":63348.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $15.58, and the range of prices was between $15.55 and $15.64. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":752217,"source":{"system":"sec-edgar","filing":"0001415889-24-020461","document":"form4-07312024_050701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924020461/form4-07312024_050701.xml","form_type":"4"}},{"id":1455134,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-12T21:15:07.000Z","date":"2024-07-11","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":12.26,"value":61300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.26, and the range of prices was between $12.23 and $12.33. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":756283,"source":{"system":"sec-edgar","filing":"0001415889-24-019528","document":"form4-07122024_050702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924019528/form4-07122024_050702.xml","form_type":"4"}},{"id":1462002,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-02T21:30:28.000Z","date":"2024-06-28","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":10.77,"value":215400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $10.77, and the range of prices was between $10.55 and $11.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":761283,"source":{"system":"sec-edgar","filing":"0001415889-24-018975","document":"form4-07022024_050720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924018975/form4-07022024_050720.xml","form_type":"4"}},{"id":1474410,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-18T21:00:23.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":23000,"derivative":{"exercise_price":12.36,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001415889-24-017443","document":"form4-06182024_050609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924017443/form4-06182024_050609.xml","form_type":"4"}},{"id":1491293,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T01:00:06.000Z","date":"2024-06-04","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":12.33,"value":61650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $12.33, and the range of prices was between $12.23 and $12.43. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":781283,"source":{"system":"sec-edgar","filing":"0001415889-24-015508","document":"form4-06042024_090601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924015508/form4-06042024_090601.xml","form_type":"4"}},{"id":1491292,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T01:00:06.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":10.93,"value":54650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $10.93, and the range of prices was between $10.91 and $11.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":786283,"source":{"system":"sec-edgar","filing":"0001415889-24-015508","document":"form4-06042024_090601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924015508/form4-06042024_090601.xml","form_type":"4"}},{"id":1491291,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T01:00:06.000Z","date":"2024-05-31","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":9.41,"value":141150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $9.41, and the range of prices was between $9.34 and $9.56. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":791283,"source":{"system":"sec-edgar","filing":"0001415889-24-015508","document":"form4-06042024_090601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924015508/form4-06042024_090601.xml","form_type":"4"}},{"id":1524270,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-07T21:00:39.000Z","date":"2024-05-06","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":10.92,"value":54600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $10.92, and the range of prices was between $10.91 and $10.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":806283,"source":{"system":"sec-edgar","filing":"0001415889-24-012485","document":"form4-05072024_050502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924012485/form4-05072024_050502.xml","form_type":"4"}},{"id":1530212,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-02T21:09:12.000Z","date":"2024-04-30","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":9.51,"value":142650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $9.51, and the range of prices was between $9.20 and $9.91. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":811283,"source":{"system":"sec-edgar","filing":"0001415889-24-012020","document":"form4-05022024_090504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924012020/form4-05022024_090504.xml","form_type":"4"}},{"id":1557387,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-29T21:00:14.000Z","date":"2024-03-28","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":10.97,"value":219400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $10.97, and the range of prices was between $10.80 and $11.20. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":826283,"source":{"system":"sec-edgar","filing":"0001415889-24-009445","document":"form4-03292024_050302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924009445/form4-03292024_050302.xml","form_type":"4"}},{"id":1602212,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T22:30:15.000Z","date":"2024-02-29","kind":"sale","planned":true,"acquired":false,"shares":100,"price":13,"value":1300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $13.00, and the range of prices was between $12.97 and $13.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":846283,"source":{"system":"sec-edgar","filing":"0001415889-24-006322","document":"form4-03042024_050305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924006322/form4-03042024_050305.xml","form_type":"4"}},{"id":1602211,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-04T22:30:15.000Z","date":"2024-02-29","kind":"sale","planned":true,"acquired":false,"shares":24900,"price":12.41,"value":309009.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.41, and the range of prices was between $11.94 and $12.86. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":846383,"source":{"system":"sec-edgar","filing":"0001415889-24-006322","document":"form4-03042024_050305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924006322/form4-03042024_050305.xml","form_type":"4"}},{"id":1660593,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T22:00:09.000Z","date":"2024-02-01","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":15.56,"value":77800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $15.56, and the range of prices was between $15.55 and $15.59. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":871283,"source":{"system":"sec-edgar","filing":"0001415889-24-002350","document":"form4-02022024_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924002350/form4-02022024_050201.xml","form_type":"4"}},{"id":1660592,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T22:00:09.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":12.23,"value":305750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.23, and the range of prices was between $12.03 and $12.38. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":876283,"source":{"system":"sec-edgar","filing":"0001415889-24-002350","document":"form4-02022024_050201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924002350/form4-02022024_050201.xml","form_type":"4"}},{"id":1696031,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-02T22:30:06.000Z","date":"2023-12-29","kind":"sale","planned":false,"acquired":false,"shares":2500,"price":14.1,"value":35250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $14.10, and the range of prices was between $14.08 and $14.27. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":901283,"source":{"system":"sec-edgar","filing":"0001415889-24-000070","document":"form4-01022024_050101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924000070/form4-01022024_050101.xml","form_type":"4"}},{"id":1696030,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-02T22:30:06.000Z","date":"2023-12-29","kind":"sale","planned":false,"acquired":false,"shares":22500,"price":13.3,"value":299250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $13.30, and the range of prices was between $13.15 and $13.87. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":903783,"source":{"system":"sec-edgar","filing":"0001415889-24-000070","document":"form4-01022024_050101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924000070/form4-01022024_050101.xml","form_type":"4"}},{"id":1725009,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T22:15:05.000Z","date":"2023-11-30","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":12.57,"value":314250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.57, and the range of prices was between $12.30 and $13.02. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":926283,"source":{"system":"sec-edgar","filing":"0001415889-23-015701","document":"form4-12012023_051201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923015701/form4-12012023_051201.xml","form_type":"4"}},{"id":1730711,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-23T00:00:23.000Z","date":"2023-11-22","kind":"sale","planned":false,"acquired":false,"shares":3989,"price":13.9,"value":55447.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a\ndiscretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $13.90, and the range of prices was between $13.62 and $14.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":951283,"source":{"system":"sec-edgar","filing":"0001415889-23-015457","document":"form4-11222023_071105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923015457/form4-11222023_071105.xml","form_type":"4"}},{"id":1730710,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-23T00:00:23.000Z","date":"2023-11-21","kind":"sale","planned":false,"acquired":false,"shares":4192,"price":14.86,"value":62293.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a\ndiscretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $14.86, and the range of prices was between $14.26 and $15.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":955272,"source":{"system":"sec-edgar","filing":"0001415889-23-015457","document":"form4-11222023_071105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923015457/form4-11222023_071105.xml","form_type":"4"}},{"id":1730709,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-23T00:00:23.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 11, 2022, the Reporting Person was granted certain performance restricted stock units (\"PRSUs\") for 45,000 shares, which are subject to vesting\nupon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on\nNovember 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria."}],"balance_after":959464,"source":{"system":"sec-edgar","filing":"0001415889-23-015457","document":"form4-11222023_071105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923015457/form4-11222023_071105.xml","form_type":"4"}},{"id":1751033,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-03T00:50:40.000Z","date":"2023-11-02","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":15.64,"value":78200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $15.64, and the range of prices were between $15.55 and $15.75. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":943714,"source":{"system":"sec-edgar","filing":"0001415889-23-014714","document":"form4-11032023_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923014714/form4-11032023_121146.xml","form_type":"4"}},{"id":1751032,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-03T00:50:40.000Z","date":"2023-10-31","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":12.05,"value":301250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.05, and the range of prices were between $11.19 and $13.24. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":948714,"source":{"system":"sec-edgar","filing":"0001415889-23-014714","document":"form4-11032023_121146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923014714/form4-11032023_121146.xml","form_type":"4"}},{"id":1766466,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T21:00:34.000Z","date":"2023-09-29","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":12.41,"value":310250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.41, and the range of prices were between $11.86 and $13.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":973714,"source":{"system":"sec-edgar","filing":"0001415889-23-013898","document":"form4-10032023_051008.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923013898/form4-10032023_051008.xml","form_type":"4"}},{"id":1788691,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-06T01:08:08.000Z","date":"2023-09-05","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":11.62,"value":116200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $11.62, and the range of prices were between $10.91 and $12.34. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":998714,"source":{"system":"sec-edgar","filing":"0001415889-23-012922","document":"form4-09062023_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923012922/form4-09062023_010901.xml","form_type":"4"}},{"id":1788690,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-06T01:08:08.000Z","date":"2023-08-31","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":9.36,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $9.36, and the range of prices were between $9.22 and $9.60. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1008714,"source":{"system":"sec-edgar","filing":"0001415889-23-012922","document":"form4-09062023_010901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923012922/form4-09062023_010901.xml","form_type":"4"}},{"id":1788689,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-05T20:05:23.000Z","date":"2023-08-16","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":10.14,"value":152100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 17, 2023, the reporting person filed a Form 4 that inadvertently excluded the weighted average sale price for the transaction. This amendment is being filed solely to report that the weighted average sale price for the transaction reported was $10.14, and the range of prices were between $9.765 and $10.65. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1023714,"source":{"system":"sec-edgar","filing":"0001415889-23-012898","document":"form4a-09052023_040904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923012898/form4a-09052023_040904.xml","form_type":"4/A","original_submission_date":"2023-08-17"}},{"id":1802821,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:00:19.000Z","date":"2023-08-16","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":10.14,"value":152100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023."}],"balance_after":1023714,"source":{"system":"sec-edgar","filing":"0001415889-23-012360","document":"form4-08172023_050801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923012360/form4-08172023_050801.xml","form_type":"4"}},{"id":1859963,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T21:30:05.000Z","date":"2023-06-08","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":6.3,"value":63000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $6.30, and the range of prices were between $6.30 and $6.32. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1038714,"source":{"system":"sec-edgar","filing":"0001415889-23-009522","document":"form4-06092023_050601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923009522/form4-06092023_050601.xml","form_type":"4"}},{"id":1863430,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-08T01:30:09.000Z","date":"2023-06-06","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":6.295,"value":31475.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $6.295, and the range of prices were between $6.24 and $6.37. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1048714,"source":{"system":"sec-edgar","filing":"0001415889-23-009406","document":"form4-06072023_090601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923009406/form4-06072023_090601.xml","form_type":"4"}},{"id":1863429,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-08T01:30:09.000Z","date":"2023-06-05","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":6.045,"value":30225.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $6.045 and the range of prices were between $5.96 and $6.10. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,568 shares acquired under the issuer's Employee Stock Purchase Plan."}],"balance_after":1053714,"source":{"system":"sec-edgar","filing":"0001415889-23-009406","document":"form4-06072023_090601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923009406/form4-06072023_090601.xml","form_type":"4"}},{"id":2035001,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Research Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-02T22:23:24.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.87,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-23-006279","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919123006279/doc4.xml","form_type":"4"}},{"id":2412774,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T00:10:39.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":104500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":104500,"derivative":{"exercise_price":7.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":104500},"source":{"system":"sec-edgar","filing":"0001415889-22-001059","document":"form4-02032022_040230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588922001059/form4-02032022_040230.xml","form_type":"4"}},{"id":2490210,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-12-01T22:34:56.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":400,"price":24.76,"value":9904.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $24.76, and the range of prices were between $24.75 and $24.80. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1051146,"source":{"system":"sec-edgar","filing":"0001415889-21-005622","document":"form4-12012021_021248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921005622/form4-12012021_021248.xml","form_type":"4"}},{"id":2537057,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-10-21T20:33:23.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":4555,"price":28.2,"value":128451.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $28.20, and the range of prices were between $28.00 and $28.63. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1051546,"source":{"system":"sec-edgar","filing":"0001415889-21-004934","document":"form4-10212021_011011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921004934/form4-10212021_011011.xml","form_type":"4"}},{"id":2537056,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-10-21T20:33:23.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":7445,"price":27.85,"value":207343.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $27.85, and the range of prices were between $27.60 and $28.00. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1056101,"source":{"system":"sec-edgar","filing":"0001415889-21-004934","document":"form4-10212021_011011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921004934/form4-10212021_011011.xml","form_type":"4"}},{"id":2562620,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-09-21T22:19:13.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":12000,"price":26.3,"value":315600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $26.30, and the range of prices were between $25.95 and $26.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1063546,"source":{"system":"sec-edgar","filing":"0001415889-21-004513","document":"form4-09212021_030906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921004513/form4-09212021_030906.xml","form_type":"4"}},{"id":2594399,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-08-21T01:14:14.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":12000,"price":24.97,"value":299640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $24.97, and the range of prices were between $24.75 and $25.46. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1075546,"source":{"system":"sec-edgar","filing":"0001415889-21-004029","document":"form4-08202021_060804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921004029/form4-08202021_060804.xml","form_type":"4"}},{"id":2627867,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-07-21T21:29:39.000Z","date":"2021-07-20","kind":"sale","acquired":false,"shares":4123,"price":25.63,"value":105672.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $25.63, and the range of prices were between $25.14 and $26.10. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1087546,"source":{"system":"sec-edgar","filing":"0001415889-21-003664","document":"form4-07212021_020727.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921003664/form4-07212021_020727.xml","form_type":"4"}},{"id":2627866,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-07-21T21:29:39.000Z","date":"2021-07-19","kind":"sale","acquired":false,"shares":7877,"price":24.83,"value":195585.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $24.83, and the range of prices were between $24.75 and $24.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1091669,"source":{"system":"sec-edgar","filing":"0001415889-21-003664","document":"form4-07212021_020727.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921003664/form4-07212021_020727.xml","form_type":"4"}},{"id":2659867,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-06-21T23:05:36.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":600,"price":26.3,"value":15780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"2. The weighted average sale price for the transaction reported was $26.30, and the range of prices were between $26.19 and $26.99. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1099546,"source":{"system":"sec-edgar","filing":"0001415889-21-003129","document":"form4-06212021_040621.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921003129/form4-06212021_040621.xml","form_type":"4"}},{"id":2659866,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-06-21T23:05:36.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":1990,"price":25.59,"value":50924.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $25.59, and the range of prices were between $25.16 and $26.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1100146,"source":{"system":"sec-edgar","filing":"0001415889-21-003129","document":"form4-06212021_040621.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921003129/form4-06212021_040621.xml","form_type":"4"}},{"id":2659865,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2021-06-21T23:05:36.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":9410,"price":24.54,"value":230921.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $24.54, and the range of prices were between $24.18 and $25.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":1102136,"source":{"system":"sec-edgar","filing":"0001415889-21-003129","document":"form4-06212021_040621.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921003129/form4-06212021_040621.xml","form_type":"4"}},{"id":2969377,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-11-23T21:31:48.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":122028,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":122028},"source":{"system":"sec-edgar","filing":"0001209191-20-059971","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059971/doc4.xml","form_type":"4"}},{"id":2969376,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-11-23T21:31:48.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":71374,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":71374},"source":{"system":"sec-edgar","filing":"0001209191-20-059971","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059971/doc4.xml","form_type":"4"}},{"id":2969375,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2020-11-23T21:31:48.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":122028,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager."}],"balance_after":122028,"source":{"system":"sec-edgar","filing":"0001209191-20-059971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059971/doc4.xml","form_type":"4"}},{"id":2969374,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2020-11-23T21:31:48.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":71374,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock."}],"balance_after":1111546,"source":{"system":"sec-edgar","filing":"0001209191-20-059971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059971/doc4.xml","form_type":"4"}},{"id":2970756,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-20T23:42:11.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":1076,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By daughter"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1076,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":1076},"source":{"system":"sec-edgar","filing":"0001209191-20-059759","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059759/doc4a.xml","form_type":"4/A","original_submission_date":"2020-11-19"}},{"id":2972603,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:43:30.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":179340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":179340,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":179340},"source":{"system":"sec-edgar","filing":"0001209191-20-059512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059512/doc4.xml","form_type":"4"}},{"id":2972602,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-19T23:43:30.000Z","date":"2020-09-12","kind":"grant","acquired":true,"shares":227859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 48 successive equal monthly installments measured from September 12, 2020, subject to the\nReporting Person's continuous service through each applicable vesting date."}],"balance_after":227859,"derivative":{"exercise_price":4.824,"expiration_date":"2030-09-11","underlying":"Common Stock","underlying_shares":227859},"source":{"system":"sec-edgar","filing":"0001209191-20-059512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059512/doc4.xml","form_type":"4"}},{"id":2972601,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":28488,"kind":"person","name":"Harmon Cyrus","position":1,"cik":"0001831410","reported_name":"Harmon Cyrus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2020-11-19T23:43:30.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":143472,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1040172,"source":{"system":"sec-edgar","filing":"0001209191-20-059512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059512/doc4.xml","form_type":"4"}}]}